July 28, 2025 4:34pm

As the cell and gene therapy sector operated hazardously on a slim advance/decline lines and pricing margins

Volatility will likely be a result of sector earnings this week

Earnings this week: 7/29, Tuesday = uniQure NV (QURE), 7/30, Wednesday = MiMedx (MDXG), 7/31, Thursday = Alnylam Pharmaceuticals (ALNY), Vericel (VCERL), 8/1 = Ionis Pharmaceuticals (IONS) and Moderna (MRNA), 8/5, Tuesday = AxoGen (AXGN)

Never above you. Never below you. Always beside you … I say what others won’t, so you can do what others can’t!

Never leave an investor uninformed!  

My perspective is retail investors should roll-the-dice with econ readings until earnings season kicks-in and momentum wains in the cell and gene therapy sector. NO all ins as historically “our” universe slips and slides as the “season’ resumes; so, hang-in with those with solid partners, lengthened runways and solid cash positions leveraged by solid/stable management teams!

 

Monday’s RegMed Investors’ (RMi) pre-open: Drop the sails, batten the hatches and cruise … https://www.regmedinvestors.com/articles/14015

Friday night’s RegMed Investors (RMi) Closing Bell: cell and gene therapy sector breathes in a new high … https://www.regmedinvestors.com/articles/14014

RegMed Investors (RMi) Research Note: Sustaining a Loser … https://www.regmedinvestors.com/articles/13812

 

Monday: The Dow closed DOWN -64.36 points or -0.14%, the S&P closed UP +1.13 points or +0.02% while the Nasdaq closed UP +70.27 points or +0.33%

  • Theme of the session, bracing for a busy econ and market/sector catalyst week

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy

  • On deck this week includes the Fed’s interest rate decision, Friday’s jobs report and Labor Turnover Survey, or JOLTS, on Tuesday, ADP’s private payrolls report on Wednesday and weekly jobless claims Thursday with 7 cell and gene therapy sector earnings season initiating

Monday’s advance/decline line opened positive with 17 incliners, 11 decliners and 7 flats ending with a negative close of 14 incliners, 16 decliners and 5 flats      

Metrics:  Monday, the IBB was down -1.39%, the XBI was down -1.17% while the VIX was up +0.08 points or +0.54% at 15.01

 

Q3 – 7/25 – 1 market holiday, 14 positive and 6 negative closes

Q2/25:

  • June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes
  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 11 positive and 10 negative closes

 

Monday Closing UP (10 of 14) +$ after Friday’s

  • Vericel (VCEL +$1.33 after Friday’s +$0.40),
  • Agenus (AGEN +$0.29 after Friday’s -$0.08),
  • Cellectis SA (CLLS +$0.33 after Friday’s +$0.52),
  • Ultragenyx Pharmaceuticals (RARE +$0.27),
  • Generation Bio (GBIO +$0.09 after Friday’s +$0.41),
  • Fate Therapeutics (FATE +$0.06),
  • Voyager Therapeutics (VYGR +$0.03),
  • Solid Biosciences (SLDB +$0.02 after Friday’s +$0.32),
  • Compass Therapeutics (CMPX +$0.02),
  • MiMedx (MDXG +$0.02 after Friday’s -$0.08),

Flat (5)

  • bluebird bio (BLUE) P/E acquired
  • Blueprint Medicine (BPMC) acquired by SNY
  • Harvard Apparatus RT (OTCQB: HRGN) - a Ponzi scheme
  • Homology Medicine (FIXX)
  • Verve Therapeutics (VERV) – acquired by LLY

Monday’s Closing DOWN (10 of xx): -$ after Friday’s

  • Alnylam Pharmaceuticals ALNY -$4.02 after Friday’s +$0.81),
  • Ionis Pharmaceuticals (IONS -$1.08),
  • CRISPR Therapeutics (CRSP -$1.01 after Friday’s -$1.30),
  • Beam Therapeutics (BEAM -$0.89 after Friday’s +$0.77),
  • Intellia Therapeutics (NTLA -$0.49 after Friday’s +$0.82),
  • Mesoblast (MESO -$0.43 after Friday’s -$0.62),
  • AxoGen (AXGN -$0.38 after Friday’s +$0.16),
  • BioLife Solutions (BLFS -$0.35),
  • Moderna (MRNA -$0.24 after Friday’s +$0.14)
  • Editas Medicine (EDIT -$0.19 after Friday’s -$0.11),

 

The BOTTOM LINE: Today’s story … cell and gene therapy stocks wavered on Monday to a negative close even after good news of the US and European Union striking a trade pact.

  • However, sector investor “worried” eyes should be focused on upcoming earnings releases, and a jam-packed econ week.

Beyond earnings, the Fed begins its 2-day policy meeting on Tuesday, with an interest-rate decision expected Wednesday. While the central bank is expected to keep rates at 4.25%-4.50%, the watch is on for signs that policymakers are warming to a rate cut in September. It all comes alongside Trump's general pressure on the central bank and Chair Jerome Powell. <Yahoo Finance>

  • On the data front, inflation and labor will be in the spotlight. The July reading of the personal consumption expenditures (PCE) index, the Fed’s preferred inflation gauge, is forecast to show a modest monthly and annual uptick on its release on Thursday.

Maybe after all, I should have taken this week off … to avoid the nervous and the on-coming pain

 

The cell and gene therapy sector closed negative on Monday (7/28) …

  • Having closed positive on Friday after Thursday’s negative close following Wednesday (7/23), Tuesday and Monday’s positive closes …
  • After slipping last Friday (7/18) following a positive close on last Thursday and Wednesday having slid on Tuesday after Monday’s positive close
  • And popping on the previous Friday, Thursday and Wednesday continued the upside after Tuesday positive close and diving on Monday ….
  • After the previous, previous week’s pop on multiple positive closes (Thursday, Wednesday, Tuesday and Monday) in this new month, July and Q.

 

Earnings are a’comin: 7/29, Tuesday = uniQure NV (QURE), 7/30, Wednesday = MiMedx (MDXG), 7/31, Thursday = Alnylam Pharmaceuticals (ALNY), Vericel (VCERL), 8/1 = Ionis Pharmaceuticals (IONS) and Moderna (MRNA), 8/5, Tuesday = AxoGen (AXGN)

As I also wrote, the “June Swoon” is over … however, July is much better than past months. Although, I consider the so-called summer rally … peripatetic or wandering.”

  • There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

 

July disolves this week: understand the “flow” …

  • 7/28 – Monday closed negative with 14 positive, 16 negative and 5 flats

Last week:

  • 7/25 – Friday closed positive with 17 positive, 14 negative and 4 flats
  • 7/24 – Thursday closed negative with 7 positive, 25 negative and 3 flats
  • 7/23 – Wednesday closed positive with 30 positive, 1 negative and 4 flats
  • 7/22 – Tuesday closed positive with 19 positive, 10 negative and 6 flats
  • 7/21 – Monday closed positive with 17 positive, 14 negative and 4 flats

The previous week:

  • 7/18 – Friday closed negative with 10 positive, 21 negative and 4 flats
  • 7/17 – Thursday closed positive with 17 positive, 14 negative and 4 flats
  • 7/16 - Wednesday closed positive with 24 positive, 5 negative and 6 flats
  • 7/15 – Tuesday closed negative with 3 positive, 29 negative and 3 flats
  • 7/14 - Monday closed positive with 20 positive, 11 negative and 4 flats

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Monday: Vericel (VCEL), Agenus (AGEN) and Cellectis SA (CLLS)
  • Friday: Intellia Therapeutics (NTLA), Alnylam Pharmaceuticals (ALNY) and Beam Therapeutics (BEAM)

The worst three (3) in the session: 

  • Monday: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and CRISPR Therapeutics (CRSP)
  • Friday: Lenz Pharmaceuticals (LENZ), CRISPR Therapeutics (CRSP) and Mesoblast (MESO)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.